{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:27:05Z","timestamp":1793834825274,"version":"4.6.1"},"reference-count":131,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018609","name":"High-level Hospital Construction Project of Guangdong Provincial People's Hospital","doi-asserted-by":"publisher","award":["DFJH201923"],"award-info":[{"award-number":["DFJH201923"]}],"id":[{"id":"10.13039\/501100018609","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003785","name":"Guangdong Medical Research Foundation","doi-asserted-by":"publisher","award":["A2019063"],"award-info":[{"award-number":["A2019063"]}],"id":[{"id":"10.13039\/501100003785","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100238"],"award-info":[{"award-number":["82100238"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","award":["202201011046"],"award-info":[{"award-number":["202201011046"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.blre.2024.101207","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T15:42:57Z","timestamp":1713368577000},"page":"101207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Current status and prospect of anti-amyloid fibril therapy in AL amyloidosis"],"prefix":"10.1016","volume":"66","author":[{"given":"Jinghua","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liye","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2024.101207_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101040","article-title":"State-of-the-art review on AL amyloidosis in Western countries: epidemiology, health economics, risk assessment and therapeutic management of a rare disease","volume":"59","author":"Sabinot","year":"2023","journal-title":"Blood Rev"},{"issue":"6","key":"10.1016\/j.blre.2024.101207_bb0010","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/ajh.26569","article-title":"Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment","volume":"97","author":"Gertz","year":"2022","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.blre.2024.101207_bb0015","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40271-017-0273-5","article-title":"Light chain (AL) amyloidosis: the journey to diagnosis","volume":"11","author":"McCausland","year":"2018","journal-title":"Patient"},{"issue":"1","key":"10.1016\/j.blre.2024.101207_bb0020","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40164-021-00236-z","article-title":"Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications","volume":"10","author":"Xu","year":"2021","journal-title":"Exp Hematol Oncol"},{"issue":"2","key":"10.1016\/j.blre.2024.101207_bb0025","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2141.2002.03438.x","article-title":"Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis","volume":"117","author":"Harrison","year":"2002","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.blre.2024.101207_bb0030","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1182\/blood.V98.7.2266","article-title":"Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis","volume":"98","author":"Hayman","year":"2001","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2024.101207_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12041624","article-title":"The landscape of cytogenetic aberrations in light-chain amyloidosis with or without coexistent multiple myeloma","volume":"12","author":"He","year":"2023","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.blre.2024.101207_bb0040","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2016-10-743997","article-title":"Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry","volume":"129","author":"Kourelis","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2024.101207_bb0045","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s10875-011-9582-y","article-title":"A reappraisal of immunoglobulin variable gene primers and its impact on assessing clonal relationships between PB B cells and BM plasma cells in AL amyloidosis","volume":"31","author":"Katoh","year":"2011","journal-title":"J Clin Immunol"},{"issue":"31","key":"10.1016\/j.blre.2024.101207_bb0050","doi-asserted-by":"crossref","first-page":"5162","DOI":"10.1021\/bi5007892","article-title":"Decreased amyloidogenicity caused by mutational modulation of surface properties of the immunoglobulin light chain BRE variable domain","volume":"53","author":"Kobayashi","year":"2014","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/j.blre.2024.101207_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005169","article-title":"Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis","volume":"4","author":"Poshusta","year":"2009","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.blre.2024.101207_bb0060","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/febs.16390","article-title":"Antibodies gone bad - the molecular mechanism of light chain amyloidosis","volume":"290","author":"Absmeier","year":"2023","journal-title":"FEBS J"},{"issue":"76","key":"10.1016\/j.blre.2024.101207_bb0065","doi-asserted-by":"crossref","first-page":"10664","DOI":"10.1039\/C8CC04396E","article-title":"Immunoglobulin light chain amyloid aggregation","volume":"54","author":"Blancas-Mejia","year":"2018","journal-title":"Chem Commun (Camb)"},{"issue":"1","key":"10.1016\/j.blre.2024.101207_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23010319","article-title":"Classification of amyloidosis by model-assisted mass spectrometry-based proteomics","volume":"23","author":"Palstrom","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"49","key":"10.1016\/j.blre.2024.101207_bb0075","doi-asserted-by":"crossref","first-page":"16572","DOI":"10.1074\/jbc.RA120.013461","article-title":"Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis","volume":"295","author":"Lavatelli","year":"2020","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.blre.2024.101207_bb0080","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3109\/13506120009146437","article-title":"Glycosylation of immunoglobulin light chains associated with amyloidosis","volume":"7","author":"Omtvedt","year":"2000","journal-title":"Amyloid"},{"issue":"10","key":"10.1016\/j.blre.2024.101207_bb0085","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1038\/s41375-020-0940-8","article-title":"N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression","volume":"34","author":"Dispenzieri","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.blre.2024.101207_bb0090","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1038\/s41375-022-01599-w","article-title":"An N-glycosylation hotspot in immunoglobulin kappa light chains is associated with AL amyloidosis","volume":"36","author":"Nevone","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.blre.2024.101207_bb0095","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.bpc.2011.05.011","article-title":"Glycosaminoglycans promote fibril formation by amyloidogenic immunoglobulin light chains through a transient interaction","volume":"158","author":"Martin","year":"2011","journal-title":"Biophys Chem"},{"issue":"8","key":"10.1016\/j.blre.2024.101207_bb0100","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1074\/jbc.M114.615401","article-title":"Differential effects on light chain amyloid formation depend on mutations and type of glycosaminoglycans","volume":"290","author":"Blancas-Mejia","year":"2015","journal-title":"J Biol Chem"},{"issue":"48","key":"10.1016\/j.blre.2024.101207_bb0105","doi-asserted-by":"crossref","first-page":"37672","DOI":"10.1074\/jbc.M110.149575","article-title":"Role of glycosaminoglycan sulfation in the formation of immunoglobulin light chain amyloid oligomers and fibrils","volume":"285","author":"Ren","year":"2010","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.blre.2024.101207_bb0110","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1099-1352(200007\/08)13:4<198::AID-JMR499>3.0.CO;2-D","article-title":"Binding of nascent collagen by amyloidogenic light chains and amyloid fibrillogenesis in monolayers of human fibrocytes","volume":"13","author":"Harris","year":"2000","journal-title":"J Mol Recognit"},{"issue":"2","key":"10.1016\/j.blre.2024.101207_bb0115","doi-asserted-by":"crossref","first-page":"p28","DOI":"10.1159\/000071288","article-title":"Insights into mechanisms responsible for mesangial alterations associated with fibrogenic glomerulopathic light chains","volume":"94","author":"Teng","year":"2003","journal-title":"Nephron Physiol"},{"key":"10.1016\/j.blre.2024.101207_bb0120","doi-asserted-by":"crossref","first-page":"29096","DOI":"10.1038\/srep29096","article-title":"In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study","volume":"6","author":"Ami","year":"2016","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.blre.2024.101207_bb0125","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCHEARTFAILURE.108.788687","article-title":"Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition","volume":"1","author":"Biolo","year":"2008","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.blre.2024.101207_bb0130","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijcard.2015.03.179","article-title":"SAP: structure, function, and its roles in immune-related diseases","volume":"187","author":"Xi","year":"2015","journal-title":"Int J Cardiol"},{"issue":"22","key":"10.1016\/j.blre.2024.101207_bb0135","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.201700236","article-title":"MALDI mass spectrometry imaging: a novel tool for the identification and classification of amyloidosis","volume":"17","author":"Winter","year":"2017","journal-title":"Proteomics"},{"issue":"1","key":"10.1016\/j.blre.2024.101207_bb0140","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ajpath.2010.11.015","article-title":"Evidence for a functional role of the molecular chaperone clusterin in amyloidotic cardiomyopathy","volume":"178","author":"Greene","year":"2011","journal-title":"Am J Pathol"},{"issue":"1\u20133","key":"10.1016\/j.blre.2024.101207_bb0145","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bpc.2008.02.019","article-title":"Salts enhance both protein stability and amyloid formation of an immunoglobulin light chain","volume":"135","author":"Sikkink","year":"2008","journal-title":"Biophys Chem"},{"issue":"1","key":"10.1016\/j.blre.2024.101207_bb0150","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"10.1016\/j.blre.2024.101207_bb0155","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2010.75","article-title":"Cytotoxicity of amyloidogenic immunoglobulin light chains in cell culture","volume":"1","author":"Sikkink","year":"2010","journal-title":"Cell Death Dis"},{"issue":"8","key":"10.1016\/j.blre.2024.101207_bb0160","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archinte.1982.00340210037009","article-title":"Primary systemic amyloidosis: resolution of the nephrotic syndrome with melphalan and prednisone","volume":"142","author":"Kyle","year":"1982","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.blre.2024.101207_bb0165","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.blre.2017.03.002","article-title":"Light chain amyloidosis: where are the light chains from and how they play their pathogenic role?","volume":"31","author":"Zhang","year":"2017","journal-title":"Blood Rev"},{"issue":"4","key":"10.1016\/j.blre.2024.101207_bb0170","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0735-1097(97)00267-2","article-title":"Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement","volume":"30","author":"Reisinger","year":"1997","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.blre.2024.101207_bb0175","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1093\/ndt\/gfp201","article-title":"Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney","volume":"24","author":"Gertz","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.blre.2024.101207_bb0180","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/PAP.0000000000000056","article-title":"Renal involvement in monoclonal gammopathy","volume":"22","author":"Al-Hussain","year":"2015","journal-title":"Adv Anat Pathol"},{"issue":"9","key":"10.1016\/j.blre.2024.101207_bb0185","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1093\/ndt\/gfq831","article-title":"Renal amyloidosis revisited: amyloid distribution, dynamics and biochemical type","volume":"26","author":"Hopfer","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.blre.2024.101207_bb0190","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ndt\/gfr381","article-title":"Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney","volume":"27","author":"Eirin","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.blre.2024.101207_bb0195","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1468-1331.2010.03215.x","article-title":"Peripheral nerve involvement in primary systemic AL amyloidosis: a clinical and electrophysiological study","volume":"18","author":"Matsuda","year":"2011","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1016\/j.blre.2024.101207_bb0200","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000495455","article-title":"Recent advances in the diagnosis, risk stratification, and management of systemic light-chain amyloidosis","volume":"141","author":"Vaxman","year":"2019","journal-title":"Acta Haematol"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2024.101207_bb0205","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.amjmed.2022.01.006","article-title":"Neuromuscular complications of systemic amyloidosis","volume":"135","author":"Namiranian","year":"2022","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.blre.2024.101207_bb0210","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2169\/internalmedicine.9206-17","article-title":"Nationwide survey of 741 patients with systemic amyloid light-chain amyloidosis in Japan","volume":"57","author":"Shimazaki","year":"2018","journal-title":"Intern Med"},{"issue":"1","key":"10.1016\/j.blre.2024.101207_bb0215","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1080\/07853890.2022.2069281","article-title":"The clinical features and outcomes of systemic light chain amyloidosis with hepatic involvement","volume":"54","author":"Zhao","year":"2022","journal-title":"Ann Med"},{"issue":"12","key":"10.1016\/j.blre.2024.101207_bb0220","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13469","article-title":"Intestinal involvement in amyloidosis is a sequential process","volume":"30","author":"den Braber-Ymker","year":"2018","journal-title":"Neurogastroenterol Motil"},{"issue":"2","key":"10.1016\/j.blre.2024.101207_bb0225","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/qjmed\/91.2.141","article-title":"The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement","volume":"91","author":"Dubrey","year":"1998","journal-title":"QJM"},{"issue":"22","key":"10.1016\/j.blre.2024.101207_bb0230","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.2174\/1568026611212220007","article-title":"Amyloid formation in light chain amyloidosis","volume":"12","author":"Ramirez-Alvarado","year":"2012","journal-title":"Curr Top Med Chem"},{"issue":"2","key":"10.1016\/j.blre.2024.101207_bb0235","doi-asserted-by":"crossref","first-page":"247","DOI":"10.5858\/arpa.2016-0102-RA","article-title":"Amyloidosis of the lung","volume":"141","author":"Khoor","year":"2017","journal-title":"Arch Pathol Lab Med"},{"issue":"145","key":"10.1016\/j.blre.2024.101207_bb0240","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0046-2017","article-title":"The lung in amyloidosis","volume":"26","author":"Milani","year":"2017","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.blre.2024.101207_bb0245","article-title":"Pulmonary AL amyloidosis: a review and update on treatment options","volume":"80","author":"Moy","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"issue":"4","key":"10.1016\/j.blre.2024.101207_bb0250","first-page":"353","article-title":"Immunoglobulin-related (AL) amyloidosis","volume":"1","author":"Husby","year":"1983","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.blre.2024.101207_bb0255","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.mayocp.2016.06.027","article-title":"Systemic immunoglobulin light chain amyloidosis-associated myopathy: presentation, diagnostic pitfalls, and outcome","volume":"91","author":"Muchtar","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.blre.2024.101207_bb0260","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1525-139x.2001.00032.x","article-title":"The role of the synovium and cartilage in the pathogenesis of beta(2)-microglobulin amyloidosis","volume":"14","author":"Moe","year":"2001","journal-title":"Semin Dial"},{"key":"10.1016\/j.blre.2024.101207_bb0265","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.938582","article-title":"Case report of 59-year-old woman with bilateral upper limb musculoskeletal amyloid, initially diagnosed as rheumatoid arthritis","volume":"24","author":"Bui","year":"2023","journal-title":"Am J Case Rep"},{"issue":"40","key":"10.1016\/j.blre.2024.101207_bb0270","doi-asserted-by":"crossref","first-page":"27513","DOI":"10.1074\/jbc.M114.585638","article-title":"Formation of amyloid fibers by monomeric light chain variable domains","volume":"289","author":"Brumshtein","year":"2014","journal-title":"J Biol Chem"},{"issue":"49","key":"10.1016\/j.blre.2024.101207_bb0275","doi-asserted-by":"crossref","first-page":"14848","DOI":"10.1021\/bi00253a024","article-title":"Comparison of crystal structures of two homologous proteins: structural origin of altered domain interactions in immunoglobulin light-chain dimers","volume":"33","author":"Huang","year":"1994","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.blre.2024.101207_bb0280","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.bbapap.2015.04.024","article-title":"The study of transient protein-nanoparticle interactions by solution NMR spectroscopy","volume":"1864","author":"Assfalg","year":"2016","journal-title":"Biochim Biophys Acta Proteins Proteomics"},{"issue":"18","key":"10.1016\/j.blre.2024.101207_bb0285","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1111\/febs.14181","article-title":"Heat-induced native dimerization prevents amyloid formation by variable domain from immunoglobulin light-chain REI","volume":"284","author":"Nawata","year":"2017","journal-title":"FEBS J"},{"issue":"3","key":"10.1016\/j.blre.2024.101207_bb0290","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1073\/pnas.1817538116","article-title":"Role of domain interactions in the aggregation of full-length immunoglobulin light chains","volume":"116","author":"Rennella","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2024.101207_bb0295","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.10935","article-title":"Inhibition by small-molecule ligands of formation of amyloid fibrils of an immunoglobulin light chain variable domain","volume":"4","author":"Brumshtein","year":"2015","journal-title":"Elife"},{"issue":"17","key":"10.1016\/j.blre.2024.101207_bb0300","doi-asserted-by":"crossref","first-page":"8360","DOI":"10.1073\/pnas.1817567116","article-title":"Stabilization of amyloidogenic immunoglobulin light chains by small molecules","volume":"116","author":"Morgan","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"10.1016\/j.blre.2024.101207_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127356","article-title":"Structural basis for the stabilization of amyloidogenic immunoglobulin light chains by hydantoins","volume":"30","author":"Yan","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.blre.2024.101207_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2023.102319","article-title":"Pharmacological stabilization of the native state of full-length immunoglobulin light chains to treat light chain amyloidosis","volume":"75","author":"Yan","year":"2023","journal-title":"Curr Opin Chem Biol"},{"issue":"9","key":"10.1016\/j.blre.2024.101207_bb0315","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1021\/acs.jmedchem.1c00339","article-title":"Discovery of potent coumarin-based kinetic stabilizers of amyloidogenic immunoglobulin light chains using structure-based design","volume":"64","author":"Yan","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.blre.2024.101207_bb0320","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bbrc.2022.01.066","article-title":"Compound screening identified gossypetin and isoquercitrin as novel inhibitors for amyloid fibril formations of Vlambda6 proteins associated with AL amyloidosis","volume":"596","author":"Takahashi","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"10.1016\/j.blre.2024.101207_bb0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052686","article-title":"AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils","volume":"7","author":"Wall","year":"2012","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.blre.2024.101207_bb0330","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/13506129.2016.1205974","article-title":"2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis (dagger)","volume":"23","author":"Renz","year":"2016","journal-title":"Amyloid"},{"issue":"14","key":"10.1016\/j.blre.2024.101207_bb0335","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood.2022019406","article-title":"Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial","volume":"142","author":"Gertz","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2024.101207_bb0340","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","article-title":"First-in-human phase I\/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction","volume":"34","author":"Gertz","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2024.101207_bb0345","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clml.2019.10.019","article-title":"Dual monoclonal antibody therapy in patients with systemic AL amyloidosis and cardiac involvement","volume":"20","author":"Godara","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.blre.2024.101207_bb0350","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1021\/bi0616605","article-title":"Localization of a conformational epitope common to non-native and fibrillar immunoglobulin light chains","volume":"46","author":"O\u2019Nuallain","year":"2007","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/j.blre.2024.101207_bb0355","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0002-9440(10)64639-1","article-title":"Antibody-mediated resolution of light chain-associated amyloid deposits","volume":"157","author":"Hrncic","year":"2000","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.blre.2024.101207_bb0360","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/ajcp\/100.1.67","article-title":"Production and immunodiagnostic applications of antihuman light chain monoclonal antibodies","volume":"100","author":"Abe","year":"1993","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.blre.2024.101207_bb0365","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0076-6879(99)09016-3","article-title":"In vitro immunoglobulin light chain fibrillogenesis","volume":"309","author":"Wall","year":"1999","journal-title":"Methods Enzymol"},{"issue":"10 Pt 2","key":"10.1016\/j.blre.2024.101207_bb0370","first-page":"3831S","article-title":"Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4","volume":"9","author":"Solomon","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.blre.2024.101207_bb0375","first-page":"2016","article-title":"Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibody","volume":"47","author":"Wall","year":"2006","journal-title":"J Nucl Med"},{"issue":"13","key":"10.1016\/j.blre.2024.101207_bb0380","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1182\/blood-2010-03-273797","article-title":"Radioimmunodetection of amyloid deposits in patients with AL amyloidosis","volume":"116","author":"Wall","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2024.101207_bb0385","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/bjh.16436","article-title":"Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits","volume":"189","author":"Popkova","year":"2020","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.blre.2024.101207_bb0390","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s11864-021-00922-4","article-title":"Immunotherapy in AL amyloidosis","volume":"23","author":"Zhang","year":"2022","journal-title":"Curr Treat Options Oncol"},{"issue":"46","key":"10.1016\/j.blre.2024.101207_bb0395","doi-asserted-by":"crossref","first-page":"E10839","DOI":"10.1073\/pnas.1805515115","article-title":"Bifunctional amyloid-reactive peptide promotes binding of antibody 11-1F4 to diverse amyloid types and enhances therapeutic efficacy","volume":"115","author":"Wall","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.blre.2024.101207_bb0400","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jaccao.2022.08.009","article-title":"AL amyloidosis for cardiologists: awareness, diagnosis, and future prospects: JACC: cardiooncology state-of-the-art review","volume":"4","author":"Wechalekar","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"10","key":"10.1016\/j.blre.2024.101207_bb0405","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1073\/pnas.92.10.4299","article-title":"Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis","volume":"92","author":"Tennent","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.blre.2024.101207_bb0410","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.amjmed.2005.08.043","article-title":"Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis","volume":"119","author":"Hazenberg","year":"2006","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.blre.2024.101207_bb0415","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2967\/jnumed.106.039313","article-title":"Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis","volume":"48","author":"Hazenberg","year":"2007","journal-title":"J Nucl Med"},{"issue":"422","key":"10.1016\/j.blre.2024.101207_bb0420","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan3128","article-title":"Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis","volume":"10","author":"Richards","year":"2018","journal-title":"Sci Transl Med"},{"issue":"7320","key":"10.1016\/j.blre.2024.101207_bb0425","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature09494","article-title":"Antibodies to human serum amyloid P component eliminate visceral amyloid deposits","volume":"468","author":"Bodin","year":"2010","journal-title":"Nature"},{"issue":"6886","key":"10.1016\/j.blre.2024.101207_bb0430","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/417254a","article-title":"Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis","volume":"417","author":"Pepys","year":"2002","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.blre.2024.101207_bb0435","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1365-2141.2009.08036.x","article-title":"Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis","volume":"148","author":"Gillmore","year":"2010","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.blre.2024.101207_bb0440","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic clearance of amyloid by antibodies to serum amyloid P component","volume":"373","author":"Richards","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2024.101207_bb0445","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12872-021-02407-6","article-title":"Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label phase 2 study and an adjunctive immuno-PET imaging study","volume":"22","author":"Wechalekar","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"10.1016\/j.blre.2024.101207_bb0450","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13023-022-02405-7","article-title":"An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study","volume":"17","author":"Richards","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"34","key":"10.1016\/j.blre.2024.101207_bb0455","doi-asserted-by":"crossref","first-page":"E586","DOI":"10.1073\/pnas.1103247108","article-title":"In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides","volume":"108","author":"Wall","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.blre.2024.101207_bb0460","doi-asserted-by":"crossref","first-page":"7657","DOI":"10.3390\/molecules20057657","article-title":"Preclinical validation of the heparin-reactive peptide p5+14 as a molecular imaging agent for visceral amyloidosis","volume":"20","author":"Wall","year":"2015","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.blre.2024.101207_bb0465","doi-asserted-by":"crossref","DOI":"10.3390\/ph16040629","article-title":"Clinical confirmation of pan-amyloid reactivity of radioiodinated peptide (124)I-p5+14 (AT-01) in patients with diverse types of systemic amyloidosis demonstrated by PET\/CT imaging","volume":"16","author":"Martin","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"Suppl B","key":"10.1016\/j.blre.2024.101207_bb0470","doi-asserted-by":"crossref","first-page":"B79","DOI":"10.1093\/eurheartjsupp\/suad079","article-title":"Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis","volume":"25","author":"Emdin","year":"2023","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.blre.2024.101207_bb0475","doi-asserted-by":"crossref","first-page":"1275372","DOI":"10.3389\/fimmu.2023.1275372","article-title":"Development and characterization of a prototypic pan-amyloid clearing agent - a novel murine peptide-immunoglobulin fusion","volume":"14","author":"Foster","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.blre.2024.101207_bb0480","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066181","article-title":"A binding-site barrier affects imaging efficiency of high affinity amyloid-reactive peptide radiotracers in vivo","volume":"8","author":"Wall","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.blre.2024.101207_bb0485","doi-asserted-by":"crossref","first-page":"1073503","DOI":"10.3389\/fcvm.2022.1073503","article-title":"Changing paradigm in the treatment of amyloidosis: from disease-modifying drugs to anti-fibril therapy","volume":"9","author":"Quarta","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.blre.2024.101207_bb0490","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ijcard.2020.07.016","article-title":"Doxycycline decreases amyloidogenic light chain-induced autophagy in isolated primary cardiac myocytes","volume":"321","author":"Valero-Munoz","year":"2020","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.blre.2024.101207_bb0495","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.005868","article-title":"Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis","volume":"2","author":"Tanaka","year":"2013","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.blre.2024.101207_bb0500","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/j.1523-1755.2005.00571.x","article-title":"Matrix metalloproteinases and mesangial remodeling in light chain-related glomerular damage","volume":"68","author":"Keeling","year":"2005","journal-title":"Kidney Int"},{"issue":"25","key":"10.1016\/j.blre.2024.101207_bb0505","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1182\/blood-2011-04-351643","article-title":"Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis","volume":"118","author":"Ward","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2024.101207_bb0510","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.26","article-title":"Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis","volume":"7","author":"Wechalekar","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2024.101207_bb0515","article-title":"Adjuvant doxycycline to enhance anti-amyloid effects: results from the dual phase 2 trial","volume":"23","author":"D\u2019Souza","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"3","key":"10.1016\/j.blre.2024.101207_bb0520","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/13506129.2022.2155809","article-title":"The impact of post-transplant doxycycline in AL amyloidosis - updated results after long-term follow up","volume":"30","author":"Abdallah","year":"2023","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.blre.2024.101207_bb0525","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCULATIONAHA.121.055953","article-title":"Doxycycline combined with bortezomib-cyclophosphamide-dexamethasone chemotherapy for newly diagnosed cardiac light-chain amyloidosis: a multicenter randomized controlled trial","volume":"145","author":"Shen","year":"2022","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.blre.2024.101207_bb0530","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1021\/ja3115696","article-title":"Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrils","volume":"135","author":"Palhano","year":"2013","journal-title":"J Am Chem Soc"},{"issue":"6","key":"10.1016\/j.blre.2024.101207_bb0535","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1074\/jbc.M116.750323","article-title":"Aggregation of full-length immunoglobulin light chains from systemic light chain amyloidosis (AL) patients is remodeled by epigallocatechin-3-gallate","volume":"292","author":"Andrich","year":"2017","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.blre.2024.101207_bb0540","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1182\/blood-2007-05-089243","article-title":"Epigallocathechin-3-gallate in AL amyloidosis: a new therapeutic option?","volume":"110","author":"Hunstein","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2024.101207_bb0545","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00392-008-0649-6","article-title":"Therapy effects of green tea in a patient with systemic light-chain amyloidosis","volume":"97","author":"Mereles","year":"2008","journal-title":"Clin Res Cardiol"},{"issue":"8","key":"10.1016\/j.blre.2024.101207_bb0550","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00392-010-0142-x","article-title":"Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis","volume":"99","author":"Mereles","year":"2010","journal-title":"Clin Res Cardiol"},{"issue":"3","key":"10.1016\/j.blre.2024.101207_bb0555","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12185-016-2112-1","article-title":"Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis","volume":"105","author":"Meshitsuka","year":"2017","journal-title":"Int J Hematol"},{"issue":"9","key":"10.1016\/j.blre.2024.101207_bb0560","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.clml.2019.03.029","article-title":"Fibril-directed therapies in systemic light chain AL amyloidosis","volume":"19","author":"Bhutani","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"10.1016\/j.blre.2024.101207_bb0565","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1073\/pnas.92.7.2959","article-title":"Interaction of the anthracycline 4\u2032-iodo-4\u2032-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis","volume":"92","author":"Merlini","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.blre.2024.101207_bb0570","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood.V86.3.855.855","article-title":"New drug therapy of amyloidoses: resorption of AL-type deposits with 4\u2032-iodo-4\u2032-deoxydoxorubicin","volume":"86","author":"Gianni","year":"1995","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2024.101207_bb0575","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood.V93.3.1112","article-title":"Treatment of AL amyloidosis with 4\u2032-lodo-4\u2032-deoxydoxorubicin: an update","volume":"93","author":"Merlini","year":"1999","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2024.101207_bb0580","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3109\/13506120209072441","article-title":"A multicenter phase II trial of 4\u2032-iodo-4\u2019deoxydoxorubicin (IDOX) in primary amyloidosis (AL)","volume":"9","author":"Gertz","year":"2002","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.blre.2024.101207_bb0585","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/08982104.2013.838258","article-title":"Nanoliposomes protect against AL amyloid light chain protein-induced endothelial injury","volume":"24","author":"Truran","year":"2014","journal-title":"J Liposome Res"},{"issue":"6","key":"10.1016\/j.blre.2024.101207_bb0590","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003318","article-title":"Monosialoganglioside-containing nanoliposomes restore endothelial function impaired by AL amyloidosis light chain proteins","volume":"5","author":"Franco","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.blre.2024.101207_bb0595","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/08982104.2016.1274756","article-title":"PEGylated-nanoliposomal clusterin for amyloidogenic light chain-induced endothelial dysfunction","volume":"28","author":"Guzman-Villanueva","year":"2018","journal-title":"J Liposome Res"},{"issue":"12","key":"10.1016\/j.blre.2024.101207_bb0600","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.jcyt.2017.08.021","article-title":"Mesenchymal stromal cells protect human cardiomyocytes from amyloid fibril damage","volume":"19","author":"Lin","year":"2017","journal-title":"Cytotherapy"},{"issue":"5","key":"10.1016\/j.blre.2024.101207_bb0605","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/s41375-019-0640-4","article-title":"Light chain amyloidosis induced inflammatory changes in cardiomyocytes and adipose-derived mesenchymal stromal cells","volume":"34","author":"Jordan","year":"2020","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.blre.2024.101207_bb0610","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.exphem.2010.07.001","article-title":"Inhibition of pathologic immunoglobulin-free light chain production by small interfering RNA molecules","volume":"38","author":"Phipps","year":"2010","journal-title":"Exp Hematol"},{"issue":"12","key":"10.1016\/j.blre.2024.101207_bb0615","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/gt.2011.69","article-title":"Preclinical development of siRNA therapeutics for AL amyloidosis","volume":"18","author":"Hovey","year":"2011","journal-title":"Gene Ther"},{"issue":"22","key":"10.1016\/j.blre.2024.101207_bb0620","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/blood-2013-10-535187","article-title":"One siRNA pool targeting the lambda constant region stops lambda light-chain production and causes terminal endoplasmic reticulum stress","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2024.101207_bb0625","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1073\/pnas.0912263107","article-title":"Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway","volume":"107","author":"Shi","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.blre.2024.101207_bb0630","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s00395-013-0378-5","article-title":"Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity","volume":"108","author":"Guan","year":"2013","journal-title":"Basic Res Cardiol"},{"issue":"11","key":"10.1016\/j.blre.2024.101207_bb0635","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.15252\/emmm.201404190","article-title":"Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity","volume":"6","author":"Guan","year":"2014","journal-title":"EMBO Mol Med"},{"issue":"8","key":"10.1016\/j.blre.2024.101207_bb0640","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41408-021-00529-w","article-title":"Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study","volume":"11","author":"Staron","year":"2021","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.blre.2024.101207_bb0645","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1097\/TP.0000000000004230","article-title":"Clinical outcomes and effectiveness of heart transplantation in patients with systemic light-chain cardiac amyloidosis","volume":"106","author":"Jeong","year":"2022","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.blre.2024.101207_bb0650","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-022-00714-5","article-title":"Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through the international kidney and monoclonal gammopathy research group","volume":"12","author":"Havasi","year":"2022","journal-title":"Blood Cancer J"},{"issue":"25","key":"10.1016\/j.blre.2024.101207_bib651","first-page":"2632","article-title":"Phase 1a\/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis","volume":"138","author":"Camille Vanessa","year":"2021","journal-title":"Clinical Trials Agreement"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T18:36:48Z","timestamp":1718390208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X24000407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":131,"alternative-id":["S0268960X24000407"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2024.101207","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current status and prospect of anti-amyloid fibril therapy in AL amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2024.101207","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101207"}}